Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | PRCP | P42785 | 10/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380733 | 1.00 | CYP3A4 (0.51) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL2380735 | 1.00 | CYP3A4 (0.51) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL2865541 | 0.96 | PRCP (0.49) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15388455 | 0.94 | PRCP (0.46) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15388457 | 0.94 | PRCP (0.46) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL14857235 | 0.94 | PRCP (0.46) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL14857232 | 0.94 | PRCP (0.46) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15388458 | 0.94 | PRCP (0.46) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL14857233 | 0.94 | PRCP (0.46) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15388206 | 0.94 | CYP3A4 (0.46) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729077-B2 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729077-B2 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
| WO-2010062821-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062821-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, MAVS | CYP3A4 1529/4885CYP2C9 3460/4885KCNH2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.